Gary D. Steinberg, MD, FACS – Immediate Past Chair

Gary Steinberg, MD, Professor Department of Urology at the Rush University Medical Center and specializes in urologic oncology. He was previously Director of the Bladder Cancer program at NYU Langone and prior to that, the Director of Urologic Oncology at the University of Chicago.

He has been instrumental in developing innovative surgical procedures for patients with bladder cancers. He is the AUA representative to the Wound and Ostomy Continence Nursing Association for stomal therapy. In addition, Dr. Steinberg’s research includes developing new treatments for urologic cancers, especially bladder cancer. He has performed over 2,500 radical cystectomies and is a national leader in continent urinary tract reconstruction.

He has been a national principal investigator, scientific advisor and protocol development advisor for multiple innovative clinical trials and translational research studies utilizing novel agents including oncolytic vaccines and immunotherapeutic agents. He has been a key advisor in clinical trial design, protocol development, study completion and analysis for patients with high risk non-muscle invasive bladder cancer.

In addition, He is also involved with additional innovative intravesical drug delivery systems and other immunotherapy translational research studies. He has been a key protocol advisor on a number of novel neoadjuvant and adjuvant therapy trials for patients with muscle invasive bladder cancer and is currently leading the development of personalized cancer vaccines for neoadjuvant and metastatic bladder cancer.

Dr. Steinberg has been on multiple panels for the FDA and NCI and helped write the guidelines for immunotherapy of bladder cancer for the Society of Immunotherapy of Cancer (SITC). He has presented to ODAC and advised multiple companies preparing for ODAC meetings. Dr. Steinberg is the immediate past chairperson of the Scientific Advisory Board of the Bladder Cancer Advocacy Network, a member of the International Bladder cancer Group (IBCG) and serves on the executive committee of the Bladder Cancer Research Network. He has published over 250 peer reviewed papers and book chapters.